NDLI: Targeting Bone as a Therapy for Myeloma

Content Provider	Springer Nature Link
Author	Wu, Ping Morgan, Gareth J.
Copyright Year	2011
Abstract	Myeloma bone disease (BD) not only impairs quality of life, but is also associated with impaired survival. Studies of the biology underlying BD support the notion that the increased osteoclastogenesis and suppressed osteoblastogenesis, is both a consequence and a necessity for tumour growth and clonal expansion. Survival and expansion of the myeloma clone is dependent on its interactions with bone elements, thus targeting these interactions should have antimyeloma activities. Indeed both experimental and clinical findings indicate that bone-targeted therapies not only improve BD, but also create an inhospitable environment for myeloma cell growth and survival, favouring improved clinical outcome. This review summarizes recent progress in our understandings of the biology of myeloma BD, highlighting the role of osteoclasts and osteoblasts in this process and how they can be targeted therapeutically. Unravelling the mechanisms underlying myeloma-bone interactions will facilitate the development of novel therapeutic agents to treat BD, which as a consequence are likely to improve the clinical outcome of myeloma patients.
Starting Page	299
Ending Page	311
Page Count	13
File Format	PDF
ISSN	18752292
Journal	Cancer Microenvironment
Volume Number	4
Issue Number	3
e-ISSN	18752284
Language	English
Publisher	Springer Netherlands
Publisher Date	2011-08-11
Publisher Institution	International Cancer Microenvironment Society
Publisher Place	Dordrecht
Access Restriction	Subscribed
Subject Keyword	Multiple myeloma Bone disease Osteoclast Osteoblast Therapy Oncology Biomedicine general Biochemistry Cancer Research Immunology Cell Biology
Content Type	Text
Resource Type	Article
Subject	Cancer Research Oncology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Bone Anabolic Agents for the Treatment of Multiple Myeloma

Targeting bone as a therapy for myeloma.

Bone anabolic agents for the treatment of multiple myeloma.

Angiogenesis and Multiple Myeloma

CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation.

RUNX2 promotes the suppression of osteoblast function and enhancement of osteoclast activity by multiple myeloma cells.

The Hemopoietic Stem Cell Niche Versus the Microenvironment of the Multiple Myeloma-Tumor Initiating Cell

The Immune Microenvironment of Myeloma

LIGHT/TNFSF14 increases osteoclastogenesis and decreases osteoblastogenesis in multiple myeloma-bone disease.

Targeting Bone as a Therapy for Myeloma

Similar Documents

Bone Anabolic Agents for the Treatment of Multiple Myeloma

Targeting bone as a therapy for myeloma.

Bone anabolic agents for the treatment of multiple myeloma.

Angiogenesis and Multiple Myeloma

CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation.

RUNX2 promotes the suppression of osteoblast function and enhancement of osteoclast activity by multiple myeloma cells.

The Hemopoietic Stem Cell Niche Versus the Microenvironment of the Multiple Myeloma-Tumor Initiating Cell

The Immune Microenvironment of Myeloma

LIGHT/TNFSF14 increases osteoclastogenesis and decreases osteoblastogenesis in multiple myeloma-bone disease.

Targeting Bone as a Therapy for Myeloma